MA53368A - Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale - Google Patents

Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale

Info

Publication number
MA53368A
MA53368A MA053368A MA53368A MA53368A MA 53368 A MA53368 A MA 53368A MA 053368 A MA053368 A MA 053368A MA 53368 A MA53368 A MA 53368A MA 53368 A MA53368 A MA 53368A
Authority
MA
Morocco
Prior art keywords
modified
dosage forms
oral administration
release dosage
release
Prior art date
Application number
MA053368A
Other languages
English (en)
Inventor
Donald Bierer
Danja Grossbach
Tia Jacobs
Julia Küsel
Carmen Lobback
Kai Lovis
Britta Olenik
Philipp Rubenbauer
Heiko Schirmer
Peter Serno
Anke Stroyer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/043,567 external-priority patent/US10905667B2/en
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA53368A publication Critical patent/MA53368A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA053368A 2018-07-24 2019-07-19 Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale MA53368A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/043,567 US10905667B2 (en) 2018-07-24 2018-07-24 Orally administrable modified-release pharmaceutical dosage form
EP18185127 2018-07-24

Publications (1)

Publication Number Publication Date
MA53368A true MA53368A (fr) 2021-06-02

Family

ID=67314781

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053368A MA53368A (fr) 2018-07-24 2019-07-19 Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale

Country Status (22)

Country Link
EP (1) EP3826627B1 (fr)
JP (1) JP2021532113A (fr)
KR (1) KR20210035235A (fr)
CN (1) CN112469402B (fr)
AU (1) AU2019311234A1 (fr)
BR (1) BR112020026644A2 (fr)
CA (1) CA3107169A1 (fr)
CL (1) CL2021000160A1 (fr)
CO (1) CO2021000450A2 (fr)
CR (1) CR20210043A (fr)
DO (1) DOP2021000015A (fr)
EC (1) ECSP21003707A (fr)
IL (1) IL280083A (fr)
JO (1) JOP20210019A1 (fr)
MA (1) MA53368A (fr)
MX (1) MX2021000904A (fr)
PE (1) PE20210415A1 (fr)
PH (1) PH12021550170A1 (fr)
SG (1) SG11202100369WA (fr)
TW (1) TW202019402A (fr)
UY (1) UY38308A (fr)
WO (1) WO2020020789A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
EP4339184B1 (fr) * 2021-05-14 2026-08-12 Medshine Discovery Inc. Composés d'acide alkylcarboxylique et leur application
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
CN117982443B (zh) * 2022-10-31 2026-03-06 优辉药业(北京)有限公司 一种达格列净二甲双胍缓释片剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
DE3868077D1 (de) 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (fr) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Pyrimidines et triazines annelées et leur utilisation pour traiter ou prévenir des affections du système cardio-vasculaire
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
PE20211391A1 (es) 2017-12-01 2021-07-27 Bayer Pharma AG Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico

Also Published As

Publication number Publication date
WO2020020789A1 (fr) 2020-01-30
SG11202100369WA (en) 2021-02-25
EP3826627B1 (fr) 2023-10-18
PE20210415A1 (es) 2021-03-04
CO2021000450A2 (es) 2021-01-29
PH12021550170A1 (en) 2021-09-13
TW202019402A (zh) 2020-06-01
JOP20210019A1 (ar) 2021-01-24
MX2021000904A (es) 2021-03-31
CN112469402B (zh) 2024-05-14
KR20210035235A (ko) 2021-03-31
IL280083A (en) 2021-03-01
CL2021000160A1 (es) 2021-06-04
UY38308A (es) 2020-02-28
ECSP21003707A (es) 2021-02-26
CA3107169A1 (fr) 2020-01-30
EP3826627A1 (fr) 2021-06-02
CR20210043A (es) 2021-03-09
BR112020026644A2 (pt) 2021-03-23
CN112469402A (zh) 2021-03-09
AU2019311234A1 (en) 2021-02-04
JP2021532113A (ja) 2021-11-25
DOP2021000015A (es) 2021-02-15
EP3826627C0 (fr) 2023-10-18

Similar Documents

Publication Publication Date Title
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
MA52421A (fr) Composés pharmaceutiques
EP4045480A4 (fr) Formulations pharmaceutiques
EP4149460C0 (fr) Formes galéniques solides thérapeutiques
IL264210A (en) High-strength oral cannabinoid dosage forms
EP4474028A4 (fr) Système de gestion
MA51204A (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EP3875085A4 (fr) Suspension d'édaravone destinée à être administrée par voie orale
MA55015A (fr) Formulations pharmaceutiques
EP3996695A4 (fr) Comprimés de cannabidiol à désintégration orale
LT3866767T (lt) Farmacinė kompozicija, skirta peroraliniam vartojimui, apimanti aminopirimidino darinį arba jo druską
EP3914234A4 (fr) Compositions pharmaceutiques
EP3784214A4 (fr) Forme galénique pharmaceutique orale liquide
DK3914321T3 (da) Lægemiddeladministrationsanordning
EP3746080A4 (fr) Formulations pharmaceutiques
EP4015001A4 (fr) Composition pharmaceutique orale
EP3790543A4 (fr) Compositions et formes posologiques pour administration orale
EP3826627C0 (fr) Forme d'administration pharmaceutique applicable par voie orale à libération modifiée
EP3318259A4 (fr) Composition pharmaceutique stable pour administration par voie orale
EP3946296A4 (fr) Formulation pharmaceutique à libération prolongée
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
EP3638211A4 (fr) Compositions pharmaceutiques à libération prolongée retardée
DK4027973T3 (da) Formuleringer til lægemiddeladministration
MA54095A (fr) Formulations pharmaceutiques aqueuses